QOPI QCDR

  • SIGN UP FOR 2018!

    See the full list of 2018 quality measures for the QOPI Reporting Registry!

    Have questions? Contact us!

  • Quality Oncology Practice Initiative (QOPI®) Reporting Registry brought to you by ASCO and ASTRO is now available! This Qualified Clinical Data Registry (QCDR) supports continuous quality improvement that meets federal quality programs. Physicians and groups can utilize the QCDR to meet the new Medicare Merit-Based Incentive Payment System (MIPS) program. Eligible clinicians are required to participate to avoid a negative payment adjustment.

    For detailed information about the MIPS program, review the Quality Payment Program section of our website.

    The QOPI Reporting Registry is a beneficial tool that drives quality improvement without adding burden to practices. FIGmd, the experienced technology firm supporting the QCDR, developed a process to extract data from electronic health records (EHR). QOPI Reporting Registry also offers a manual data entry option. Patient data is protected in compliance with HIPPA and federal regulations. By aggregating data, sometimes from multiple EHRs, practices can monitor performance over time, compare to benchmark data, and identify gaps for improvement while satisfying federal requirements. With the QCDR designation from CMS, the QOPI Reporting Registry can create additional quality measures not currently available in federal reporting programs and therefore offers more flexibility than qualified registries. The QCDR supports all MIPS performance categories.

    For questions about the QOPI Reporting Regsitry, email ASTRO's QCDR team. Also, please also take advantage of our QOPI Reporting Registry educational tools:

  • Registration is limited to practices with at least one active ASTRO or ASCO member. To sign up, please visit the QOPI webpage and click on “New Signup”. For additional assistance, please review the Sign-Up Portal User Guide. Upon registration, practices will be contacted regarding the necessary steps to begin the on-boarding process.

    Registration for the System Integration function in 2018 is now open. Registration for the Web-Interface Tool, should be available soon.  There is a cost of $495 per physician to submit data to CMS. 

    Data can be entered into QOPI Reporting Registry in two ways, through electronic transfer or manual input.

    System Integration (SI)

    The registry platform operates regardless of the EHR utilized by a physician or group. The QOPI Reporting Registry is currently being used by practices with ARIA® and MOSAIQ® Radiation Oncology EHRs. Within SI, there are two functionalities:

    • Data Pull this approach includes a read-only extraction software that connects to the practice’s EHR database. Data relevant to the registry will be extracted automatically from the office EHR and transmitted on a scheduled basis directly to the QCDR. FIGmd and the local facility’s IT staff will work together to specialize the data extraction formula to accommodate unique data entry practice. Each set up is specific and therefore will require a set up period.
    • Data Push - this version of system integration is for facilities with strong IT capabilities and does not include the extraction software. A practice will send the EHR data to Amazon Web Service Data Warehouse via Secure File Transfer Protocol in a pre-defined HL7 or Consolidated Clinical Document Architechture (CCDA).  The practice takes on the data mapping responsibilities between the EHR data and the template.

     

    Web-interface Tool (WIT) 
    For facilities who choose to not support the EHR connection approach, the QOPI Reporting Registry also offers the Web-interface Tool (WIT). This is a method to manually input data into the system and can be utilized to report all available measures and performance categories.

    For 2018, CMS requires:

    • 6 quality measures or a specialty measure set for a full year of reporting. Individuals and groups should pick the measures that are most applicable to their practices, 
    • 1 of the measures must be an outcome or high priority measure, 
    • To ensure complete scoring of a measure (i.e. to potentially receive more than the 3-point floor), you must report on 60 percent of all your patients to whom the measure applies, and have a 20 patient minimum.

    For 2018, the QOPI Reporting Registry contains 25 measures to choose from including general medicince, medical oncology and radiation oncology. 20 of these are accepted MIPS quality measures and therefore have an associated Quality ID assigned by CMS. Review a summary of all the measure specifications. For additional specifics on the radiation oncology reportable measures, click on the measure titles below.

    MIPS Quality ID RO
    Reportable
    Measure Name
    102 Yes Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
    104 Yes Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer
    130 Yes Documentation of Current Medications in the Medical Record
    143 Yes Oncology: Medical and Radiation - Pain Intensity Quantified
    226 Yes Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
    317 Yes Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
    457 Yes Proportion Admitted to Hospice for less than 3 days
    47 Yes Care Plan
    134 Yes Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
    408 Yes Opioid Therapy Follow-up Evaluation
    456 Yes Proportion Not Admitted To Hospice
    462 Yes Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Therapy
    n/a Yes Oncology: Treatment Summary Communication – Radiation Oncology
    n/a Yes External Beam Radiotherapy for Bone Metastases
    n/a No Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented  (Lower Score - Better)
    n/a No Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) to III ER/PR negative breast cancer
    n/a No GCSF administered to patients who received chemotherapy for metastatic cancer  (Lower Score-Better)
    449 No HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies
    450 No Trastuzumab Received By Patients With AJCC Stage I (T1c) -  III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy
    451 No KRAS Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
    452 No Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies
    453 No Proportion Receiving Chemotherapy in the Last 14 Days of Life
    67 No Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
    69 No Hematology: Multiple Myeloma: Treatment with Bisphosphonates
    70 No Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry


    There are two additional quality measures that are included in the 2018 QOPI Reporting Registry that cannot be submitted for MIPS scoring, however ASTRO and ASCO are requesting that practices collect the data.  CMS has stated that these are considered Standards of Care and have limited variability of performance.  ASTRO and ASCO wants to demonstrate the variability that we know exists and would like to provide the data to CMS.

    MIPS Quality ID RO Reportable Measure Name
    n/a Yes Chemotherapy or radiation therapy for curative or palliative care cancer treatment intent documented before or within two weeks after administration
    n/a Yes Performance status documented prior to initiating chemotherapy or radiation therapy for curative or palliative care cancer treatment intent regimen

    The MIPS “Quality” Performance Category is a new iteration of the Physician Quality Reporting System (PQRS) in which eligible physicians will need to report on quality measures. For physician looking to increase their MIPS quality score and participate fully in the program, CMS requires 6 quality measures or a specialty measure set for at least 90 consecutive days. Reporting a full year may be beneficial to meet data completeness requirements but reporting longer does not automatically translate to a higher score. Individuals and groups should pick the measures that are most applicable to their practices, one of which should be an outcome measure (or a high priority measure if an outcome measure is not available and applicable). To ensure complete scoring of a measure (i.e. to potentially receive more than the 3-point floor), you must report on 50 percent of all your patients to whom the measure applies, and have a 20 patient minimum.

    For 2017, the QOPI QCDR contains 16 measures to choose from including general oncology, medical oncology and radiation oncology. 13 of these are accepted MIPS quality measures and therefore have an associated Quality ID assigned by CMS. Review a summary of all the measure specifications. For additional specifics on the radiation oncology reportable measures, click on the measure titles below.

    Quality ID  Measure       Outcome/High Priority  RO Reportable
    102 Overuse of Bone Scan X X
    104 Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer   X
    130 Documentation of Current Medication in Medical Records X X
    143 Pain Quantified X X
    226 Tobacco Use: Screening and Cessation Intervention   X
    250  Radical Prostatectomy Path Report    
    317 Screening for High Blood Pressure and Follow-Up Documented   X
    449 HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies X  
    450 Trastuzumab Received by Patients with ACJJ Stage I-III and HER 2 Positive Breast Cancer Receiving Adjuvant Chemotherapy X  
    451 KRAS Testing Performed for Patients with Metastic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor Monoclonal Antibody Therapy    
    452 Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor Monoclonal Antibodies X  
    453 Proportion Receiving Chemotherapy in the Last 14 days of Life    
    457 Proportion Admitted to Hospice for less than 3 days X X
    n/a Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1) to III ER/PR negative breast cancer    
    n/a GCSF administered to patients who received chemotherapy for metastatic cancer    
    n/a Chemotherapy administered to patients with metastatic solid tumor with performance status of 3,4, or undocumented